MPM ASSET MANAGEMENT LLC - Q3 2023 holdings

$187 Million is the total value of MPM ASSET MANAGEMENT LLC's 7 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 12.5% .

 Value Shares↓ Weighting
 Entrada Therapeutics, Inc.$69,927,387
+4.4%
4,425,7840.0%37.45%
+14.0%
DYN  Dyne Therapeutics, Inc.$44,363,675
-20.4%
4,951,3030.0%23.76%
-13.0%
ITOS  iTeos Therapeutics, Inc.$29,989,696
-17.3%
2,738,7850.0%16.06%
-9.7%
RPTX  Repare Therapeutics, Inc.$27,091,043
+14.2%
2,242,6360.0%14.51%
+24.7%
HOWL  Werewolf Therapeutics, Inc.$9,168,128
-29.8%
4,284,1720.0%4.91%
-23.4%
ADAP  Adaptimmune Therapeutics plcsponsored adr$4,903,939
-15.7%
6,287,1010.0%2.63%
-7.9%
HARP SellHarpoon Therapeutics, Inc.$1,261,938
-43.2%
313,136
-90.0%
0.68%
-38.0%
ONCR ExitOncorus, Inc.$0-2,849,464
-100.0%
-0.06%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Chiasma, Inc.24Q2 202119.8%
Aratana Therapeutics, Inc.24Q1 201926.8%
Conatus Pharmaceuticals, Inc.23Q1 20199.7%
Rhythm Pharmaceuticals, Inc.19Q2 202269.9%
Harpoon Therapeutics, Inc.19Q3 202331.9%
Syndax Pharmaceuticals, Inc.19Q3 202014.5%
Radius Health, Inc.17Q2 201876.4%
TCR2 Therapeutics, Inc.17Q1 202329.1%
Proteon Therapeutics, Inc.17Q4 20183.0%
EpiZyme, Inc.15Q4 201635.9%

View MPM ASSET MANAGEMENT LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-13
13F-HR2023-11-14
13F-HR/A2023-09-07
13F-HR2023-08-14
42023-06-05
42023-05-24
13F-HR2023-05-12
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-11

View MPM ASSET MANAGEMENT LLC's complete filings history.

Compare quarters

Export MPM ASSET MANAGEMENT LLC's holdings